Patients with Spinal Cord Injury (SCI) suffer from permanent loss of motor, sensory and autonomic functions.

There is currently no effective treatment that can regenerate the injured spinal cord and that restore those functions and unfortunately this condition has a huge economic, social and medical burden.

Matricelf is developing a complete autologous (personal) 3D neural implant that showed promising pre-clinical results by restoring motor functions in mice.  The condition can be classified as a regenerative medicine advanced therapy (RMAT) by the FDA and therefore enable the company to start a first in human clinical trial in 2024.